U.S. asthma drug costs to jump 50% by 2023
Spending on medications to fight asthma will increase from $16 billion in 2013 to $23 billion in 2023 in the eight countries where most of these drugs are purchased, and one of the main drivers will be new products for severe asthma, according to a study by the consulting company GlobalData.
“The class of fixed-dose combinations (FDCs) of inhaled corticosteroids … and long-acting beta-agonists … is the leading drug class in terms of market value,” the study states, “and currently captures almost half of the total asthma market; however, its market share will shrink to 23% as targeted biologics for the treatment of severe asthma enter the market over the forecast period and start dominating the space, growing from 8.7% to 32% of the total asthma sales.”
Providers “will see a clear shift toward personalized medicine for the treatment of severe asthmatics…. It is now clear that severe asthma is not a single disease, but rather, consists of several clinical phenotypes, each having a unique underlying pathological pathway,” the study states.
The researchers add, “The uptake of these novel drugs will be a major driver of the asthma market growth and will offset the dip in sales caused by Singulair’s (montelukast’s) recent patent expiry and the patent expiry of numerous short-acting beta-agonist … products by 2017.”
Asthma: Key Metrics, 2013–2023 | |
---|---|
2013 epidemiology | |
Asthma-diagnosed prevalent population | 60.6 million |
Asthma-treated population | 40.5 million |
2013 market sales | |
United States | $10.1B |
Worldwide | $15.9B |
Pipeline assessment | |
Number of drugs in phase 2b–3 | 8 |
Number of first-in-class drugs | 5 |
Most promising pipeline drugs | Peak-year sales |
GlaxoSmithKline’s (GSK’s) fluticasone furoate | $1.7B |
Sanofi/Regeneron’s dupilumab | $1.1B |
GSK’s Bosatria (mepolizumab) | $863M |
Teva’s Cinquil (reslizumab) | $863M |
Roche’s quilizumab | $753M |
Key events (2013–2023) | Level of impact |
Symbicort (budesonide/formoterol fumarate) patent expiration in 2014 | ↓ ↓ ↓ |
Launch of fluticasone furoate in 2015 | ↑↑↑ |
Advair Diskus (fluticasone propionate/salmeterol) patent expiration in 2016 | ↓ ↓ ↓ |
Flovent (fluticasone propionate) patent expiration in 2016 | ↓ ↓ |
Launch of Bosatria in 2016 | ↑↑ |
2023 projected market sales | |
United States | $15.3B |
Worldwide | $23.1B |
Source: Asthma – Global Drug Forecast and Market Analysis to 2023, GlobalData, August 2014 |
More like this
- Big pharma’s struggles might benefit health plans
- Outcomes and Costs Associated With Initial Maintenance Therapy With Fluticasone Propionate-Salmeterol Xinafoate 250 μg/50 μg Combination Versus Tiotropium In Commercially Insured Patients With COPD
- 80 percent of hospitalized kids prescribed off-label drugs
- Specialty drugs to spark next round of cost increases
- United States obesity, overweight rates to soar

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.